Evidence map›Paper›PMID 26525775›Full record

ReviewWorld journal of gastroenterology2015

Genetic epidemiology of irritable bowel syndrome.

Jasbir Makker, Sridhar Chilimuri, Jonathan N Bella

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome.Frontiers in cellular and infection microbiology · 2021
    Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jasbir MakkerJasbir Makker, Sridhar Chilimuri, Jonathan N Bella, Department of Medicine, Bronx-Lebanon Hospital Center and Albert Einstein College of Medicine, Bronx, NY 10457, United States.
Sridhar ChilimuriJasbir Makker, Sridhar Chilimuri, Jonathan N Bella, Department of Medicine, Bronx-Lebanon Hospital Center and Albert Einstein College of Medicine, Bronx, NY 10457, United States.
Jonathan N BellaJasbir Makker, Sridhar Chilimuri, Jonathan N Bella, Department of Medicine, Bronx-Lebanon Hospital Center and Albert Einstein College of Medicine, Bronx, NY 10457, United States.
Bronx-Lebanon Hospital Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder characterized by presence of abdominal pain or discomfort associated with altered bowel habits. It has three main subtypes - constipation predominant IBS (C-IBS), diarrhea predominant IBS (D-IBS) and IBS with mixed features of both diarrhea as well as constipation (M-IBS). Its pathophysiology and underlying mechanisms remain elusive. It is traditionally believed that IBS is a result of multiple factors including hypersensitivity of the bowel, altered bowel motility, inflammation and stress. Initial studies have shown familial aggregation of IBS suggesting shared genetic or environmental factors. Twin studies of IBS from different parts of world have shown higher concordance rates among monozygotic twins than dizygotic twins, and thus suggesting a genetic component to this disorder. Multiple studies have tried to link single-nucleotide polymorphisms (SNPs) to IBS but there is little evidence that these SNPs are functional. Various molecules have been studied and investigated by the researchers. Serotonin, a known neurotransmitter and a local hormone in the enteric nervous system, has been most extensively explored. At this time, the underlying gene pathways, genes and functional variants linked with IBS remain unknown and the promise of genetically-determined risk prediction and personalize medicine remain unfulfilled. However, molecular biological technologies continue to evolve rapidly and genetic investigations offer much promise in the intervention, treatment and prevention of IBS.

Indexed as

Genetic MarkersGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansIrritable Bowel SyndromeMolecular EpidemiologyPatient SelectionPhenotypePrecision MedicineRisk FactorsGenetic MarkersFamilial aggregationGeneticsIrritable bowel syndromeSerotoninSingle-nucleotide polymorphism

Identifiers

PMID26525775
PMCPMC4616211
OpenAlexW2182668660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.